Clinic-based retrospective analysis of psychopharmacology for behavior in fragile x syndrome.
Clinic-based retrospective analysis of psychopharmacology for behavior in fragile x syndrome.
复制标题
DOI：
10.1155/2012/843016
复制
发表时间：
2012
影响因子：
2.1
通讯作者：
Mathur S
中科院分区：
文献类型：
--
作者：
Berry-Kravis E;Sumis A;Hervey C;Mathur S
脆性X综合征（FXS）与限制功能的行为有关，包括分心、多动、冲动、过度觉醒、焦虑、情绪失调和攻击性。回顾性分析了在FXS诊所就诊的257例患者（年龄14 ± 11岁，范围4-60岁，203例男性，54例女性）的药物反应和副作用数据。治疗成功率定义为至少6个月内记录的药物治疗目标行为改善的临床报告形式的阳性反应百分比，无需要停药的副作用，而失败定义为由于缺乏临床有效性或副作用而停药。通过单独药物试验治疗目标行为的成功率为：兴奋剂为55%，抗抑郁药为53%，α 2受体激动剂为62%，抗精神病药为54%。在同一类别中进行不同药物的连续试验，成功率提高到73- 77%。抗精神病药物的副作用相关失败率最高。针对行为症状的系统性精神药理学干预似乎对大多数FXS患者有帮助。
Fragile X syndrome (FXS) is associated with behavior that limits functioning, including distractibility, hyperactivity, impulsivity, hyperarousal, anxiety, mood dysregulation, and aggression. Medication response and side effect data were reviewed retrospectively for 257 patients (age 14 ± 11 years, range 4–60 years, 203 M, 54 F) attending an FXS clinic. Treatment success rates were defined as the percentage of positive response in the form of documented clinical report of improvement in the behavior(s) being targeted over at least a 6-month period on the medication, without side effects requiring medication discontinuance, while failures were defined as discontinuance of medication due to lack of clinical effectiveness or side effects. Success rate for treatment of targeted behaviors with trials of individual medications was 55% for stimulants, 53% for antidepressants, 62% for alpha2-agonists, and 54% for antipsychotics. With sequential trials of different medications in the same class, success rate improved to 73–77%. Side effect-related failures were highest for antipsychotics. Systematic psychopharmacologic intervention targeted to behavioral symptoms appears helpful in the majority of patients with FXS.